Goldfinch Bio leverages a genomics-based, precision medicine approach and its proprietary Kidney Genome Atlas (KGA) to drive candidate discovery, patient selection and biomarker development for kidney diseases. The company’s lead candidate, GFB-887, is a first-in-class selective TRPC5 inhibitor expected to enter Phase 2 clinical studies in mid-2020 for focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). Goldfinch is also developing GFB-024, a peripherally-restricted cannabinoid receptor 1 (CB1) inverse agonist monoclonal antibody, with plans to submit an IND in 2021 to treat CB1-mediated DN. Proceeds from the Series B financing will fund advancement of GFB-887 and GFB-024 through three potential clinical proof-of-concept readouts and support continued development of the company’s discovery platform and preclinical pipeline. The company was launched in 2016 by Third Rock Ventures and has an established strategic collaboration with Gilead Sciences. Goldfinch is headquartered in Cambridge, Massachusetts. Goldfinch Bio has built a product engine that integrates genetic, genomic and biological tools to identify and validate novel drug targets and to develop precision therapies for molecularly defined patient groups. The company plans to assemble a comprehensive patient registry that combines genomic and deep phenotypic data to discover molecular drivers of kidney disease. Initial therapeutic focus areas include genetically linked conditions such as focal segmental glomerulosclerosis (FSGS) and polycystic kidney disease (PKD), with intent to apply molecular stratification to subgroups of broader chronic kidney disease populations. Goldfinch emphasizes actionable targets for intervention and aims to translate discoveries into novel treatments. The company has assembled scientific and clinical leadership including named founders and internal leaders to drive discovery and drug development. Goldfinch launched with a $55 million Series A financing to advance its therapeutic programs.

Total raised

$155M

Funding rounds

2

Latest round

Series B

Latest activity

Jun 2020